Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Impact Factor Rank: 10/24, Q2 (Tropical Medicine)
  • Users Online: 844
  • Print this page
  • Email this page

Table of Contents
Year : 2019  |  Volume : 12  |  Issue : 3  |  Page : 95-97

SARS and its treatment strategies

1 Jiangxi Academy of Medical Science, Hospital of Nanchang University, Nanchang University, Nanchang 330006, Jiangxi, China
2 Boston TransTec, LLC, Boston, MA 02459, USA

Date of Submission30-Jun-2018
Date of Decision20-Dec-2018
Date of Acceptance10-Feb-2019
Date of Web Publication27-Mar-2019

Correspondence Address:
Chun-Song Hu
Department of Cardiovascular Medicine, Jiangxi Academy of Medical Science, Hospital of Nanchang University, Nanchang University, No. 461 Bayi Ave, Nanchang 330006, Jiangxi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1995-7645.254934

Rights and Permissions

This paper briefly review severe acute respiratory syndrome, a devastating disease which broke out 15 years ago, and its treatment strategies. With the newly discovered SARSr-CoV strain in Yunnan, China, and the help of new technologies such as RNA interference, DNA vaccines, CRISPR technology and base editing, and intervention of RT-ABCDEF (iRT-ABCDEF), a standardized comprehensive program, people can better fight severe acute respiratory syndrome and other major virus-communicable diseases like highly pathogenic avian influenza and dengue fever with these powerful tools in the future.

Keywords: iRT-ABCDEF, SARSr-CoV, Severe acute respiratory syndrome, Treatment

How to cite this article:
Hu CS, Tkebuchava T. SARS and its treatment strategies. Asian Pac J Trop Med 2019;12:95-7

How to cite this URL:
Hu CS, Tkebuchava T. SARS and its treatment strategies. Asian Pac J Trop Med [serial online] 2019 [cited 2023 Jun 6];12:95-7. Available from:

  1. Introduction Top

It has been 15 years since the first outbreak of severe acute respiratory syndrome (SARS). After a novel SARS-like coronavirus (SARS-CoV) was isolated in Saudi Arabia five years ago[1], strong evidence was found that Chinese horseshoe bats are natural reservoirs of SARS-CoV[2], and that intermediate hosts may not be necessary for direct human infection. Recently, Chinese scientists have found the origin and evolution of the deadly SARSr-CoV in a remote cave in Yunnan[3]. As cardiologists in the battle against SARS, a review and perspective strategies of SARS treatment will help gather some experience and highlight the necessity of preparedness for future emergence of SARS-like diseases.

  2. SARS, SARS-CoV and treatments Top

The SARS epidemic has received worldwide attention since 2003, when Science reported several cases of SARS in Asia[4],[5],[6], especially in China. SARS, caused by a CoV variant, is called acute infectious atypical pneumonia in China. The disease was first reported in Guangdong province in November, 2002, and SARS became a new type of acute respiratory infection that seriously affected human health after its outbreak in the spring of 2003. SARS research teams in Hong Kong and Mainland China have found that CoV isolated from patients may be the main pathogen[7].

Subsequently, the World Health Organization named it SARS-CoV and confirmed that it was mainly carried by civets and raccoons. Teams on SARS investigation from the United States, Canada, Hong Kong and Mainland China reported typical clinical symptoms, complete genomic sequence, and genotypes of the SARS-CoV. High structural similarity to the human SARS-CoV nonstructural protein 3 (nsp3) is present, the “SARS-unique” region is not unique but is conserved among several different phylogenetic groups of CoV[8].

Physicians in Hong Kong first reported the successful treatment of SARS. Except for routine therapy such as oxygen inhalation and corticosteroid therapy, its treatment mainly included “antivirus drug ribavirin + a large dose of steroid hormone”. Mechanical ventilation was confirmed to be very important in the treatment of SARS. A large dose of a steroid hormone was effective at the earlier stage of SARS-CoV infection. However, disadvantages of a large dose of a steroid hormone also appeared when follow-up was done, including bone osteonecrosis.

Dr. S. C. Jiang first used the recovery serum of patients with SARS to cure himself from the infection[9], which confirmed that passive immunity for SARS therapy was effective at the earlier stage, but needed to be combined with other strategies. After the epidemic and causes of SARS in Guangdong were determined, experts from Mainland China had accumulated rich clinical experience[10], in which they combined traditional Chinese medicine such as Ginseng, Lianhuaqingwen capsules and other medicinal herbs.

Real-time quantitative polymerase chain reaction (RT-qPCR) test for SARS-CoV offers a rapid, sensitive method for early diagnosis. Sino-US scientists found that 3C-like proteinase was involved in SARS-CoV genome expression, and they have already carried out biosynthesis, purification and substrate specificity of the proteinase as well as its crystal structures and determined a 3D model. This created an opportunity for the development of anti-SARS-CoV drugs or inhibitors. Chinese scientists also established a related cell-filter-model and a series of drugs for SARS-CoV were developed.

The first SARS case in the winter of 2003 drew attention worldwide. Treatment with the strategy of “protease inhibitor + serum recovery” has achieved good clinical outcome in a short period of time. On the one hand, this strategy used protease inhibitors instead of commonly used ribavirin. The former is less toxic and does not cause obvious side effects, hence maintaining the physical strength of the patient. Protease inhibitors are a class of HIV drugs in AIDS cocktail therapy. After use, the antivirus effect is remarkable. The reason that patients can be cured in a short time is related to the application of the anti-AIDS drugs protease inhibitors. Most importantly, 3C-like proteinase is involved in the expression of the SARS-CoV genome. Therefore, protease inhibitors are ideal anti-SARS drugs or inhibitors. It can be inferred from this that if the SARS-CoV is treated as HIV and also treated by cocktail therapy, things seem much simpler and easier. Other types of drugs that can replace protease inhibitors, such as efavirenz (Sustiva)[11],[12], a non-nucleoside reverse transcriptase inhibitor developed by DuPont Pharmaceuticals, have the same effect and similar price as protease inhibitors. On the other hand, psychotherapy and humanistic care also have positive effects. In conclusion, in this case, the use of antiviral therapy, enhanced immune function and immunosuppression can achieve good results and reflect the spirit of the new “5 P” medical model[13].

In-situ hybridization study of SARS autopsy tissue indicates that SARS-CoV invades different human organs. The pathophysiological changes in the human body are not only caused by SARS-CoV itself that may impair the myocardium also by a cytokine mediated immune response. A subclinical diastolic injury was found in SARS patients without involvement of systole. This is a reminder that protecting heart and lung function is very important to avoid the occurrence and increase of death from multiple organ dysfunction syndrome.

At the same time, people also tried to use a strategy by RNA interference to inhibit SARS-CoV infection and replication[14],[15]. The 80R human monoclonal antibody may be an effective inhibitor of SARS-CoV invasion. Since the receptor binding domain of the coronavirus spike (S) protein is a key factor in determining the viral tropism and transmission capacity[16], it is also a potential target for developing subunit vaccines and drugs. The development of nucleic acid-based vaccines (DNA and mRNA vaccines) as new approaches should be continued due to the high mortality of SARS-CoV[17]. Therefore, the inactivated SARS viral vaccine is very promising and should be tested in clinical trials.

Since SARS coronavirus infection can induce acute lung injury and rapid pulmonary fibrosis, which is negatively correlated with lung function, it is important to assay serum levels of associated inflammatory cytokines in patients with severe respiratory virus infection[18],[19]. Follow-up of SARS patients showed significant functional and psychological abnormalities, including pulmonary fibrosis and vascular necrosis, and it was important to continue to track the long-term or lifelong consequences of these patients.

  3. iRT-ABCDEF for SARS and other mVCDs Top

Due to the new SARS-CoV strain found in Yunnan[3], China, the mystery of SARS prevention and management will be further revealed by the application of intervention of RT-ABCDEF (iRT-ABCDEF) [Table 1], which is applicable not only to major non-communicable diseases, for example, chronic heart failure[20], but also to major viral infectious diseases. Here, iRT-ABCDEF originated from previous RT-ABCDE[21], and means follow-up (F), examination (comprehensive or targeted) (E), disease & risk factors control (D), cut spreading pathways & change unhealthy lifestyle (C), biohazard control (B), antagonistic treatment (A). This program should be used as an intervention of routine, right, and reversible treatments (iRT). iRT-ABCDEF will be a new standardized comprehensive program to detect and control the threat of emerging infectious diseases in the future. It is also worth developing new vaccines or discovering new anti-inflammatory molecules as new biotherapeutics[22].
Table 1: iRT-ABCDEF for major virus-communicable diseases (mVCDs).

Click here to view

  4. Prospects Top

With the help of powerful tools, especially the rapid development of small science[23], new technologies such as the “molecular scissors”, CRISPR and base editing[24], can be expected to have better prospects in the fight against SARS in the future. It will help fight dengue fever in southern China[25],[26],[27].

Conflict of interest statement

The authors declared that they have no conflict of interest.


There is an ethical approval on May 25, 2018 granted by Jiangxi Academy of Medical Science, Nanchang University.

  References Top

Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-1820.  Back to cited text no. 1
Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503(7477): 535-538.  Back to cited text no. 2
Hu B, Zeng LP, Yang XL, Ge XY, Zhang W, Li B, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 2017; 13(11): e1006698.  Back to cited text no. 3
Normile D, Vogel G. Infectious diseases. Early indications point to lab infection in new SARS case. Science 2003; 301(5640): 1642-1643.  Back to cited text no. 4
Normile D. Infectious diseases. Second lab accident fuels fears about SARS. Science 2004; 303(5654): 26.  Back to cited text no. 5
Normile D. Infectious diseases. Viral DNA match spurs China’s civet roundup. Science 2004; 303(5656): 292.  Back to cited text no. 6
Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003;362(9393): 1353-1358.  Back to cited text no. 7
Hammond RG, Tan X, Johnson MA. SARS-unique fold in the Rousettus bat coronavirus HKU9. Protein Sci 2017; 26(9): 1726-1737.  Back to cited text no. 8
Jiang S, Zhang Y, Zhou X, Wang E, Yan L, Wang Y, et al. Clinical symptoms of SARS patients infected inside hospitals and results of five years of follow-up. Med J Chin PAPF 2010; 21(12): 1031-1034.  Back to cited text no. 9
Zhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome (SARS). Am J Respir Crit Care Med 2003; 168(1): 7-9.  Back to cited text no. 10
Coovadia A, Abrams EJ, Strehlau R, Shiau S, Pinillos F, Martens L, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: A randomized clinical trial. JAMA 2015; 314(17): 1808-1817.  Back to cited text no. 11
Pilalas D, Skoura L, Margariti A, Chatzopoulou F, Chatzidimitriou D, Tsachouridou O, et al. Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study. PLoS One 2018; 13(3): e0194262.  Back to cited text no. 12
Hu CS, Tkebuchava T. New “P” in medical model. Chin Med J (Engl) 2016; 129(4): 492-493.  Back to cited text no. 13
Liu C, Chen Z, Hu Y, Ji H, Yu D, Shen W, et al. Complemented palindromic small RNAs first discovered from SARS coronavirus. Genes (Basel) 2018; 9(9): pii: E442.  Back to cited text no. 14
Giulietti M, Righetti A, Cianfruglia L, Šabanovi B, Armeni T, Principato G, et al. To accelerate the Zika beat: Candidate design for RNA interference-based therapy. Virus Res 2018; 255: 133-140.  Back to cited text no. 15
Huang C, Qi J, Lu G, Wang Q, Yuan Y, Wu Y, et al. Putative receptor binding domain of bat-derived coronavirus HKU9 spike protein: Evolution of Betacoronavirus receptor binding motifs. Biochemistry 2016; 55(43): 5977-5988.  Back to cited text no. 16
Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol 2018; 9: 1963.  Back to cited text no. 17
Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J Virol 2017; 91(12): pii: e00182-17.  Back to cited text no. 18
Jia TG, Zhao JQ, Liu JH. Serum inflammatory factor and cytokines in AECOPD. Asian Pac J Trop Med 2014; 7(12): 1005-1008.  Back to cited text no. 19
Hu CS, Wu QH, Hu DY, Tkebuchava T. Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come. Chronic Dis Transl Med 2018;  Back to cited text no. 20
Hu CS. RT-ABCDE strategy for management and prevention of human diseases. Chin J Integr Med 2008; 14(2): 147-150.  Back to cited text no. 21
Loukas A, Hotez PJ, Diemert D, Yazdanbakhsh M, McCarthy JS, Correa-Oliveira R, et al. Hookworm infection. Nat Rev Dis Primers 2016; 2: 16088.  Back to cited text no. 22
Berg J. Science, big and small. Science 2017; 358(6370): 1504.  Back to cited text no. 23
Stokstad E, Pennisi E, Kaiser J, Cohen J, Couzin-Frankel J, Voosen P, et al. The runners up. Science 2017; 358(6370): 1522-1527.  Back to cited text no. 24
Tang X, Zhao S, Chiu APY, Wang X, Yang L, He D. Analysing increasing trends of Guillain-Barré Syndrome (GBS) and dengue cases in Hong Kong using meteorological data. PLoS One 2017; 12(12): e0187830.  Back to cited text no. 25
Shao Q, Herrlinger S, Zhu YN, Yang M, Goodfellow F, Stice SL, et al. The African Zika virus MR-766 is more virulent and causes more severe brain damage than current Asian lineage and dengue virus. Development 2017; 144(22): 4114-4124.  Back to cited text no. 26
Zou L, Chen J, Feng X, Ruan S. Analysis of a Dengue model with vertical transmission and application to the 2014 Dengue outbreak in Guangdong Province, China. Bull Math Biol 2018; 80(10): 2633-2651.  Back to cited text no. 27


  [Table 1]

This article has been cited by
1 Health in All Laws: A better strategy for global health
Chunsong Hu, Tengiz Tkebuchava
Journal of Evidence-Based Medicine. 2022; 15(1): 10
[Pubmed] | [DOI]
2 Analysis of COVID-19 Cases and Public Measures in China
Chun-Song Hu
SN Comprehensive Clinical Medicine. 2020; 2(9): 1306
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  2. SARS, SARS-Co...3. iRT-ABCDEF fo...
  In this article
1. Introduction
4. Prospects
Article Tables

 Article Access Statistics
    PDF Downloaded544    
    Comments [Add]    
    Cited by others 2    

Recommend this journal